ID   JH-2/TPA
AC   CVCL_V634
SY   JH-2
DR   cancercelllines; CVCL_V634
DR   CCRID; 4201PAT-CCTCC00148
DR   Wikidata; Q54898623
RX   Patent=US7632677;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200006.
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Transfected with: HGNC; 9051; PLAT.
CC   Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0317 ! HT-1080
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 20
//
RX   Patent=US7632677;
RA   Xia J.-H.;
RT   "Cell line expressing mutated human tissue-type plasminogen activator,
RT   the constructing strategy thereof and method of preparing expressed
RT   protein.";
RL   Patent number US7632677, 15-Dec-2009.
//